1. Wang, Kunyu, Zhang, Yanan, Ao, Miao, Mao, Wei, Li, Bin. 2023. Multi-omics analysis defines a cuproptosis-related prognostic model for ovarian cancer: Implication of WASF2 in cuproptosis resistance. In Life sciences, 332, 122081. doi:10.1016/j.lfs.2023.122081. https://pubmed.ncbi.nlm.nih.gov/37717621/
2. Ahn, Hye Ri, Baek, Geum Ok, Yoon, Moon Gyeong, Eun, Jung Woo, Kim, Soon Sun. 2022. Hypomethylation-mediated upregulation of the WASF2 promoter region correlates with poor clinical outcomes in hepatocellular carcinoma. In Journal of experimental & clinical cancer research : CR, 41, 158. doi:10.1186/s13046-022-02365-7. https://pubmed.ncbi.nlm.nih.gov/35477411/
3. Kitagawa, Tatsuya, Taniuchi, Keisuke, Tsuboi, Makiko, Okabayashi, Takehiro, Saibara, Toshiji. 2018. Circulating pancreatic cancer exosomal RNAs for detection of pancreatic cancer. In Molecular oncology, 13, 212-227. doi:10.1002/1878-0261.12398. https://pubmed.ncbi.nlm.nih.gov/30358104/
4. Yao, Qunyan, Tu, Chuantao, Lu, Di, Liu, Hongchun, Zhang, Shuncai. 2017. Clinicopathological significance of the microRNA-146a/WASP-family verprolin-homologous protein-2 axis in gastric cancer. In Cancer science, 108, 1285-1292. doi:10.1111/cas.13254. https://pubmed.ncbi.nlm.nih.gov/28387985/
5. Yang, Xiaofeng, Ding, Yuzhen, Sun, Lu, Huang, Zhengrui, Li, Ruiman. 2022. WASF2 Serves as a Potential Biomarker and Therapeutic Target in Ovarian Cancer: A Pan-Cancer Analysis. In Frontiers in oncology, 12, 840038. doi:10.3389/fonc.2022.840038. https://pubmed.ncbi.nlm.nih.gov/35359421/
6. Yao, Qunyan, Cao, Zhongwei, Tu, Chuantao, Liu, Hongchun, Zhang, Shuncai. 2013. MicroRNA-146a acts as a metastasis suppressor in gastric cancer by targeting WASF2. In Cancer letters, 335, 219-24. doi:10.1016/j.canlet.2013.02.031. https://pubmed.ncbi.nlm.nih.gov/23435376/
智鼠故事 
